NCT06269133 2026-05-08Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) PatientsRegeneron PharmaceuticalsActive not recruiting1,000 enrolled